These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 26852935)
21. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors. Chen S; Liu Y; Zhou H Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925279 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Love KR; Catic A; Schlieker C; Ploegh HL Nat Chem Biol; 2007 Nov; 3(11):697-705. PubMed ID: 17948018 [TBL] [Abstract][Full Text] [Related]
23. Active site alanine mutations convert deubiquitinases into high-affinity ubiquitin-binding proteins. Morrow ME; Morgan MT; Clerici M; Growkova K; Yan M; Komander D; Sixma TK; Simicek M; Wolberger C EMBO Rep; 2018 Oct; 19(10):. PubMed ID: 30150323 [TBL] [Abstract][Full Text] [Related]
24. Self-stabilizing regulation of deubiquitinating enzymes in an enzymatic activity-dependent manner. Hou Z; Shi W; Feng J; Wang W; Zheng E; Lin H; Yu C; Li L Int J Biol Macromol; 2021 Jun; 181():1081-1091. PubMed ID: 33864866 [TBL] [Abstract][Full Text] [Related]
25. Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor. Long MJC; Lawson AP; Baggio R; Qian Y; Rozhansky L; Fasci D; El Oualid F; Weerapana E; Hedstrom L Bioorg Med Chem Lett; 2019 Jan; 29(2):204-211. PubMed ID: 30528168 [TBL] [Abstract][Full Text] [Related]
26. Molecular pathways: translational potential of deubiquitinases as drug targets. D'Arcy P; Linder S Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788 [TBL] [Abstract][Full Text] [Related]
27. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells. Zhou B; Zuo Y; Li B; Wang H; Liu H; Wang X; Qiu X; Hu Y; Wen S; Du J; Bu X Mol Cancer Ther; 2013 Aug; 12(8):1381-92. PubMed ID: 23696216 [TBL] [Abstract][Full Text] [Related]
28. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. Li L; Zhao H; Liao H; Chen J; Liu J; Chen J Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492 [TBL] [Abstract][Full Text] [Related]
29. Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer. Pal A; Donato NJ Breast Cancer Res; 2014; 16(5):461. PubMed ID: 25606592 [TBL] [Abstract][Full Text] [Related]
30. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Ritorto MS; Ewan R; Perez-Oliva AB; Knebel A; Buhrlage SJ; Wightman M; Kelly SM; Wood NT; Virdee S; Gray NS; Morrice NA; Alessi DR; Trost M Nat Commun; 2014 Aug; 5():4763. PubMed ID: 25159004 [TBL] [Abstract][Full Text] [Related]
31. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Coughlin K; Anchoori R; Iizuka Y; Meints J; MacNeill L; Vogel RI; Orlowski RZ; Lee MK; Roden RB; Bazzaro M Clin Cancer Res; 2014 Jun; 20(12):3174-86. PubMed ID: 24727327 [TBL] [Abstract][Full Text] [Related]
32. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Pal A; Young MA; Donato NJ Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841 [TBL] [Abstract][Full Text] [Related]
33. Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights. Hewings DS; Flygare JA; Bogyo M; Wertz IE FEBS J; 2017 May; 284(10):1555-1576. PubMed ID: 28196299 [TBL] [Abstract][Full Text] [Related]
34. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. Kathman SG; Xu Z; Statsyuk AV J Med Chem; 2014 Jun; 57(11):4969-74. PubMed ID: 24870364 [TBL] [Abstract][Full Text] [Related]
35. The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. Wang H; Ju D; Kho DH; Yang H; Li L; Raz A; Sun F; Xie Y Biochem Biophys Res Commun; 2019 Feb; 509(2):348-353. PubMed ID: 30585151 [TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mistry H; Hsieh G; Buhrlage SJ; Huang M; Park E; Cuny GD; Galinsky I; Stone RM; Gray NS; D'Andrea AD; Parmar K Mol Cancer Ther; 2013 Dec; 12(12):2651-62. PubMed ID: 24130053 [TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome. Gu X; Ma S Anticancer Agents Med Chem; 2018; 18(12):1656-1673. PubMed ID: 30101718 [TBL] [Abstract][Full Text] [Related]
38. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth. Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329 [TBL] [Abstract][Full Text] [Related]
39. [Research progress on ubiquitin-specific protease in antiviral immunity]. Zhu HH; Zhao XB; Hu WW; Chen WL Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 44(5):578-83. PubMed ID: 26713535 [TBL] [Abstract][Full Text] [Related]
40. Engineering ubiquitin to modulate the ubiquitin proteosome system. Ernst A; Sidhu SS Cell Cycle; 2013 Jun; 12(11):1651-2. PubMed ID: 23673323 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]